Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Potentiation of the Therapeutic Efficacy of Oncolytic Vaccinia using High-throughput RNAi Technology
FY 2010-11
Summary
Cancer continues to be a leading cause of death worldwide despite decades of research focused on finding a cure. While improvements have been made in conventional care (i.e. surgery, radiation and chemotherapy), and some new drug therapies targeting specific cancer cell defects have been developed, these have not proved sufficient to stem the tide of the disease. Consequently, innovative treatment modalities such as oncolytic virus therapy (OVT) are being considered. Oncolytic viruses (OVs) are viruses that specifically target and destroy cancer cells, while leaving normal cells unharmed. OVT has been making strides in recent years. Remarkable outcomes have been observed in pre-clinical and clinical studies. In fact, a number of OVs have been approved for Phase III clinical trials. Nevertheless, OVT has not been successful against all tumours. In order for OVT to move further ahead, a greater appreciation of the factors that govern the ability of an oncolytic virus to specifically target and kill tumour cells is needed. In our opinion, an approach that could lead to a comprehensive understanding of these factors is unbiased high-throughput (HT)-RNAi screening. With HT-RNAi technology one can ascertain how every gene in the human genome impacts on oncolytic viral activity in both normal and cancer cells. Equipped with this information, we believe it could allow one to design drugs to work synergistically with OVs and thereby enhance their effectiveness. Our plan is to test this approach with a genetically engineered Vaccinia virus that is set to enter a phase III clinical trial in early 2011. Our hope is that the information we glean from the HT-RNAi genome-wide screen and follow-up studies will enable us to design a drug that will work in concert with Vaccinia to improve its cancer killing ability. The outcome of this project has the potential of significantly improving cancer treatment outcomes and the lives of those fighting this devastating disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
226624
Name
Allan Kristina J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Potentiation of the Therapeutic Efficacy of Oncolytic Vaccinia using High-throughput RNAi Technology
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biotherapeutics; Cancer Therapy; Cellular Pathways; Drug Combination Therapy; Functional Genomics; High-Throughput Screening; Host/Virus Interactions; Molecular Medicine; Oncolytic Virus Therapy; Rnai
Abstract
Cancer continues to be a leading cause of death worldwide despite decades of research focused on finding a cure. While improvements have been made in conventional care (i.e. surgery, radiation and chemotherapy), and some new drug therapies targeting specific cancer cell defects have been developed, these have not proved sufficient to stem the tide of the disease. Consequently, innovative treatment modalities such as oncolytic virus therapy (OVT) are being considered. Oncolytic viruses (OVs) are viruses that specifically target and destroy cancer cells, while leaving normal cells unharmed. OVT has been making strides in recent years. Remarkable outcomes have been observed in pre-clinical and clinical studies. In fact, a number of OVs have been approved for Phase III clinical trials. Nevertheless, OVT has not been successful against all tumours. In order for OVT to move further ahead, a greater appreciation of the factors that govern the ability of an oncolytic virus to specifically target and kill tumour cells is needed. In our opinion, an approach that could lead to a comprehensive understanding of these factors is unbiased high-throughput (HT)-RNAi screening. With HT-RNAi technology one can ascertain how every gene in the human genome impacts on oncolytic viral activity in both normal and cancer cells. Equipped with this information, we believe it could allow one to design drugs to work synergistically with OVs and thereby enhance their effectiveness. Our plan is to test this approach with a genetically engineered Vaccinia virus that is set to enter a phase III clinical trial in early 2011. Our hope is that the information we glean from the HT-RNAi genome-wide screen and follow-up studies will enable us to design a drug that will work in concert with Vaccinia to improve its cancer killing ability. The outcome of this project has the potential of significantly improving cancer treatment outcomes and the lives of those fighting this devastating disease.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Allan, Kristina J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~